BEIGF - BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
2025-08-06 07:52:27 ET
More on BeOne Medicines
- BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
- BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
- BeiGene Q2 2025 Earnings Preview
- BeOne Medicines' Tevimbra gets CHMP endorsement
- Seeking Alpha’s Quant Rating on BeiGene